Literature DB >> 15380516

Binding at and transactivation of the COX-2 promoter by nuclear tyrosine kinase receptor ErbB-2.

Shao-Chun Wang1, Huang-Chun Lien, Weiya Xia, I-Fen Chen, Hui-Wen Lo, Zhiqin Wang, Mohamed Ali-Seyed, Dung-Fang Lee, Geoffrey Bartholomeusz, Fu Ou-Yang, Dipak K Giri, Mien-Chie Hung.   

Abstract

Pathological expression of human ErbB-2 protein, also known as HER-2, is common in many types of cancer. ErbB-2 is a member of the EGF receptor tyrosine kinase family and has been rigorously studied as a signaling molecule on the cell membrane. Here, we report that ErbB-2 is also expressed in the nucleus in cultured cells as well as primary tumor tissues. Nuclear ErbB-2 was found to associate with multiple genomic targets in vivo, including the cyclooxygenase enzyme COX-2 gene promoter. ErbB-2 forms a complex at a specific nucleotide sequence of the COX-2 promoter and is able to stimulate its transcription. This study demonstrates the presence of ErbB-2 in the nucleus and identifies the function of ErbB-2 as a transcriptional regulator.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15380516     DOI: 10.1016/j.ccr.2004.07.012

Source DB:  PubMed          Journal:  Cancer Cell        ISSN: 1535-6108            Impact factor:   31.743


  136 in total

1.  HER2 overexpression elicits a proinflammatory IL-6 autocrine signaling loop that is critical for tumorigenesis.

Authors:  Zachary C Hartman; Xiao-Yi Yang; Oliver Glass; Gangjun Lei; Takuya Osada; Sandeep S Dave; Michael A Morse; Timothy M Clay; Herbert K Lyerly
Journal:  Cancer Res       Date:  2011-04-25       Impact factor: 12.701

2.  H2O2 induces nuclear transport of the receptor tyrosine kinase c-MET in breast cancer cells via a membrane-bound retrograde trafficking mechanism.

Authors:  Mei-Kuang Chen; Yi Du; Linlin Sun; Jennifer L Hsu; Yu-Han Wang; Yuan Gao; Jiaxing Huang; Mien-Chie Hung
Journal:  J Biol Chem       Date:  2019-04-08       Impact factor: 5.157

3.  An adenoviral vaccine encoding full-length inactivated human Her2 exhibits potent immunogenicty and enhanced therapeutic efficacy without oncogenicity.

Authors:  Zachary C Hartman; Junping Wei; Takuya Osada; Oliver Glass; Gangjun Lei; Xiao-Yi Yang; Sharon Peplinski; Dong-Wan Kim; Wenle Xia; Neil Spector; Jeffrey Marks; William Barry; Amy Hobeika; Gayathri Devi; Andrea Amalfitano; Michael A Morse; H Kim Lyerly; Timothy M Clay
Journal:  Clin Cancer Res       Date:  2010-02-23       Impact factor: 12.531

Review 4.  The ErbB2 signaling network as a target for breast cancer therapy.

Authors:  Ali Badache; Anthony Gonçalves
Journal:  J Mammary Gland Biol Neoplasia       Date:  2006-01       Impact factor: 2.673

5.  Endosomal transport of ErbB-2: mechanism for nuclear entry of the cell surface receptor.

Authors:  Dipak K Giri; Mohamed Ali-Seyed; Long-Yuan Li; Dung-Fang Lee; Pin Ling; Geoffrey Bartholomeusz; Shao-Chun Wang; Mien-Chie Hung
Journal:  Mol Cell Biol       Date:  2005-12       Impact factor: 4.272

Review 6.  A disorganized innervation of the inner ear persists in the absence of ErbB2.

Authors:  Jacqueline K Morris; Adel Maklad; Laura A Hansen; Feng Feng; Christian Sorensen; Kuo-Fen Lee; Wendy B Macklin; Bernd Fritzsch
Journal:  Brain Res       Date:  2006-04-21       Impact factor: 3.252

7.  Differential Expression of Key Signaling Proteins in MCF10 Cell Lines, a Human Breast Cancer Progression Model.

Authors:  Jae Young So; Hong Jin Lee; Pavel Kramata; Audrey Minden; Nanjoo Suh
Journal:  Mol Cell Pharmacol       Date:  2012-01-01

Review 8.  The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis.

Authors:  M M Moasser
Journal:  Oncogene       Date:  2007-04-30       Impact factor: 9.867

Review 9.  Trafficking of receptor tyrosine kinases to the nucleus.

Authors:  Graham Carpenter; Hong-Jun Liao
Journal:  Exp Cell Res       Date:  2008-10-11       Impact factor: 3.905

10.  Cyclooxygenase-2 expression in primary breast cancers predicts dissemination of cancer cells to the bone marrow.

Authors:  Anthony Lucci; Savitri Krishnamurthy; Balraj Singh; Isabelle Bedrosian; Funda Meric-Bernstam; James Reuben; Kristine Broglio; Kailash Mosalpuria; Ashutosh Lodhi; Laura Vincent; Massimo Cristofanilli
Journal:  Breast Cancer Res Treat       Date:  2008-07-29       Impact factor: 4.872

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.